Fertility drugs and ovarian cancer risk: A critical review of the literature

Annals of the New York Academy of Sciences

Volumn 1205, Issue , 2010, Pages 214-219

  Vlahos, Nikos F ^a,b   Economopoulos, Konstantinos P ^a,c   Creatsas, George ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Society of Junior Doctors   (Greece)

Author keywords

in vitro fertilization; infertility; ovarian cancer; ovulation induction

Indexed keywords

AROMATASE; CHORIONIC GONADOTROPIN; CLOMIFENE CITRATE; ESTRADIOL; ESTROGEN; ESTRONE; FERTILITY PROMOTING AGENT; GONADORELIN AGONIST; GONADOTROPIN; K RAS PROTEIN; MATRIX METALLOPROTEINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROSTAGLANDIN E2; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA;

APOPTOSIS; CANCER INVASION; CANCER RISK; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CONFERENCE PAPER; DOWN REGULATION; DRUG EFFECT; ESTROGEN THERAPY; FEMALE INFERTILITY; FERTILIZATION IN VITRO; GENE EXPRESSION REGULATION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC RECOMBINATION; HIGH RISK PATIENT; HUMAN; INFERTILITY THERAPY; MOLECULAR MECHANICS; NONHUMAN; OVARY CANCER; OVARY CARCINOMA; OVULATION INDUCTION; PROTEIN EXPRESSION; TREATMENT RESPONSE; ANIMAL; CARCINOMA; CHEMICALLY INDUCED; DRUG EFFECTS; EVALUATION STUDY; FEMALE; GENETICS; OVARIAN NEOPLASMS; PREGNANCY; RISK FACTOR;

ANIMALS; APOPTOSIS; CARCINOMA; FEMALE; FERTILITY AGENTS; HUMANS; OVARIAN NEOPLASMS; PREGNANCY; RISK FACTORS;

EID: 77957045570     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2010.05668.x     Document Type: Conference Paper

References (40)

1. Vlahos, N.F., K.P. Economopoulos & S. Fotiou. 2010. Endometriosis, in vitro fertilisation and the risk of gynaecological malignancies, including ovarian and breast cancer. Best Pract. Res. Clin. Obstet. Gynaecol. 24: 39-50.
2. Cramer, D.W. &W.R.Welch. 1983. Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J. Natl. Cancer Inst. 71: 717-721.
3. Smith, E.R. & X.X. Xu. 2008. Ovarian ageing, follicle depletion, and cancer: a hypothesis for the aetiology of epithelial ovarian cancer involving follicle depletion. Lancet Oncol. 9: 1108-1111.
4. Varma, R., T. Rollason, J.K. Gupta & E.R. Maher. 2004. Endometriosis and the neoplastic process. Reproduction 127: 293-304.
5. Baxter, S.W., E.J. Thomas & I.G. Campbell. 2001. GSTM1 null polymorphism and susceptibility to endometriosis and ovarian cancer. Carcinogenesis 22: 63-65.
6. Sato, N., H. Tsunoda, M. Nishida, et al. 2000. Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary. Cancer Res. 60: 7052-7056.
7. Obata, K. & H. Hoshiai. 2000. Common genetic changes between endometriosis and ovarian cancer. Gynecol. Obstet. Invest . 50(Suppl 1): 39-43.
8. Otsuka, J., T. Okuda, A. Sekizawa, et al. 2004. K-rasmutation may promote carcinogenesis of endometriosis leading to ovarian clear cell carcinoma.Med. Electron.Microsc. 37: 188-192.
9. Dinulescu, D.M., T.A. Ince, B.J. Quade, et al. 2005. Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat. Med. 11: 63-70.
10. Bulun, S.E. & E.R. Simpson. 2008. Aromatase expression in womens cancers. Adv. Exp. Med. Biol. 630: 112-132.
11. Seeger, H., D.Wallwiener, E. Kraemer & A.O. Mueck. 2005. Estradiol metabolites are potent mitogenic substances for human ovarian cancer cells. Eur. J. Gynaecol.Oncol. 26: 383-385.
12. ODonnell, A.J., K.G. Macleod, D.J. Burns, et al. 2005. Estrogen receptor-alpha mediates gene expression changes and growth response in ovarian cancer cells exposed to estrogen. Endocr. Relat. Cancer. 12: 851-866.
13. Yoshida, S., N. Furukawa, S. Haruta, et al. 2009. Expression profiles of genes involved in poor prognosis of epithelial ovarian carcinoma: a review. Int. J. Gynecol. Cancer. 19: 992-997.
14. Druckmann, R. & U.D. Rohr. 2002. IGF-1 in gynaecology and obstetrics: update 2002. Maturitas 41(Suppl 1): S65-S83.
15. Skirnisdottir, I., T. Seidal, E. Gerdin & B. Sorbe. 2002. The prognostic importance of p53, bcl-2, and bax in early stage epithelial ovarian carcinoma treated with adjuvant chemotherapy. Int. J. Gynecol. Cancer. 12: 265-276.
16. Anderson, N.S., Y. Bermudez, D. Badgwell, et al. 2009. Urinary levels of Bcl-2 are elevated in ovarian cancer patients. Gynecol. Oncol. 112: 60-67.
17. Whittemore, A.S., R.Harris&J. Itnyre. 1992. Characteristics relating to ovarian cancer risk: collaborative analysis of 12US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group. Am. J. Epidemiol. 136: 1184-1203.
18. Rossing, M.A., J.R. Daling, N.S. Weiss, et al. 1994. Ovarian tumors in a cohort of infertile women.N. Engl. J. Med. 331: 771-776.
19. Shapiro, S. 1995. Risk of ovarian cancer after treatment for infertility. N. Engl. J. Med. 332: 1301; author reply 1302.
20. Del Priore, G., K. Robischon & W.R. Phipps. 1995. Risk of ovarian cancer after treatment for infertility.N. Engl. J.Med. 332: 1300; author reply 1302.
21. Modan, B., E. Ron, L. Lerner-Geva, et al. 1998. Cancer incidence in a cohort of infertile women. Am. J. Epidemiol. 147: 1038-1042.
22. Brinton, L.A., E.J. Lamb, K.S. Moghissi, et al. 2004. Ovarian cancer risk after the use of ovulation-stimulating drugs. Obstet. Gynecol. 103: 1194-1203.
23. Jensen, A., H. Sharif, K. Frederiksen & S.K. Kjaer. 2009. Use of fertility drugs and risk of ovarian cancer: Danish Population Based Cohort Study. BMJ 338: b249, doi:10.1136/bmj.b249.
24. Parazzini, F., C. Pelucchi, E.Negri, et al. 2001. Use of fertility drugs and risk of ovarian cancer. Hum. Reprod. 16: 1372-1375.
25. Mosgaard, B.J., O. Lidegaard, S.K. Kjaer, et al. 1997. Infertility, fertility drugs, and invasive ovarian cancer: a case-control study. Fertil. Steril. 67: 1005-1012.
26. Ness, R.B., D.W. Cramer, M.T. Goodman, et al. 2002. Infertility, fertility drugs, and ovarian cancer: a pooled analysis of case-control studies. Am. J. Epidemiol. 155: 217-224.
27. Rossing, M.A., M.T. Tang, E.W. Flagg, et al. 2004. A casecontrol study of ovarian cancer in relation to infertility and the use of ovulation-inducing drugs. Am. J. Epidemiol. 160: 1070-1078.
28. Kashyap, S., D.Moher, M.F. Fung & Z. Rosenwaks. 2004. Assisted reproductive technology and the incidence of ovarian cancer: a meta-analysis. Obstet. Gynecol. 103: 785-794.
29. Brinton, L.A., E.J. Lamb, K.S.Moghissi, et al. 2004. Ovarian cancer risk associatedwith varying causes of infertility. Fertil. Steril. 82: 405-414.
30. Willemsen, W., R. Kruitwagen, B. Bastiaans, et al. 1993. Ovarian stimulation and granulosa-cell tumour. Lancet. 341: 986-988.
31. Tewari, K., G.S. Rose, K.D. Balderston, et al. 1998. Fertility drugs and malignant germ-cell tumour of ovary in pregnancy. Lancet 351: 957-958.
32. Tennent, B.J., K.L. Shultz, J.P. Sundberg & W.G. Beamer. 1990. Ovarian granulosa cell tumorigenesis in SWR-derived F1 hybrid mice: preneoplastic follicular abnormality and malignant disease progression. Am. J. Obstet. Gynecol. 163:625-634.
33. Hahlin, M., N. Crona, F. Knutsson & P.O. Janson. 1991. Human granulosa cell tumor: stimulation of steroidogenesis by gonadotropins in vitro. Gynecol. Oncol. 40: 201-206.
34. Unkila-Kallio, L., A. Leminen, A. Tiitinen & O. Ylikorkala. 1998. Nationwide data on falling incidence of ovarian granulose cell tumours concomitant with increasing use of ovulation inducers. Hum. Reprod. 13: 2828-2830.
35. Adewole, I.F., I.A.Babarinsa, J.O. Thomas&A.B.Ajayi. 1997. Ovarian cancer associated with ovulation induction: a case report. Afr. J. Med. Med. Sci. 26: 203-204.
36. Dietl, J. 1991. Ovulation and ovarian cancer. Lancet 338: 445.
37. Cusido, M., R. Fabregas, B.S. Pere, et al. 2007. Ovulation induction treatment and risk of borderline ovarian tumors. Gynecol. Endocrinol. 23: 373-376.
38. Venn, A., L.Watson, J. Lumley, et al. 1995.Breast and ovarian cancer incidence after infertility and in vitro fertilisation. Lancet 346: 995-1000.
39. Venn, A., L.Watson, F. Bruinsma, et al. 1999. Risk of cancer after use of fertility drugs with in-vitro fertilisation. Lancet 354: 1586-1590.
40. Lerner-Geva, L., E. Geva, J.B. Lessing, et al. 2003. The possible association between in vitro fertilization treatments and cancer development. Int. J. Gynecol. Cancer 13: 23-27.